Clinical Trials Logo

Filter by:
NCT ID: NCT05895448 Active, not recruiting - Chronic Hepatitis C Clinical Trials

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

Start date: March 1, 2018
Phase: Phase 4
Study type: Interventional

Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (IC). This cohort was compared to concurrently treated chronic hepatitis C patients who were not intravenous drug users, who signed IC in these same clinics. Follow-up expected two years after cure and relapse rates recorded. Primary end point was SVR rate and secondary end points included reinfection rates in follow-up period.

NCT ID: NCT05893979 Active, not recruiting - Myopia Clinical Trials

Myopia Control Spectacle Lens Cessation Study

BIRCH
Start date: June 23, 2023
Phase: N/A
Study type: Interventional

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.

NCT ID: NCT05891626 Active, not recruiting - Vaccination Refusal Clinical Trials

Group Intervention on Vaccine Confidence

Start date: August 2, 2023
Phase: N/A
Study type: Interventional

This study has one primary objective and two secondary objectives, with an overall goal of understanding barriers to vaccination and vaccination confidence, so that effective interventional strategies can be further developed and tested to improve vaccination outcomes in a community healthcare setting.

NCT ID: NCT05891548 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

ODYSSEY
Start date: May 31, 2023
Phase: Phase 2
Study type: Interventional

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in participants with neovascular age-related macular degeneration previously treated with intravitreal anti-vascular endothelial growth factor (VEGF) standard of care therapy. Only one eye will be chosen as the study eye.

NCT ID: NCT05891496 Active, not recruiting - Alzheimers Disease Clinical Trials

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Start date: June 20, 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participants will either get semaglutide (active medicine) or placebo (inactive dummy medicine). Which treatment participants get is decided by chance. In the following 52 weeks of treatment, all participants taking part in the study will get semaglutide. Participants must have a study partner, who is willing to take part in the study. Participants will get study medicine in a pen injector. The study partner will need to inject the study medicine into the skin of participant's stomach, thigh or upper arm once every week.

NCT ID: NCT05891119 Active, not recruiting - Atopic Dermatitis Clinical Trials

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Start date: June 3, 2023
Phase: Early Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).

NCT ID: NCT05889702 Active, not recruiting - Clinical trials for Substance Use Disorders

Kentucky Access to Recovery Evaluation

Start date: July 3, 2023
Phase:
Study type: Observational

Evaluate the long-term effectiveness of implementing vouchers as a linkage strategy in a population requiring recovery support services (RSS) when no other funding sources are available. A within-subjects study design will be used to test the effectiveness of the Kentucky Access to Recovery (KATR) last resort voucher linkage approach to reduce the risk of nonfatal and fatal overdoses by (a) increasing an individual's recovery capital; (b) reducing resumption of illicit substance use; and (c) promoting relinking to RSSs if illicit substance use is resumed.

NCT ID: NCT05887947 Active, not recruiting - Smoking Cessation Clinical Trials

Impact of E-cigarette Nicotine Concentration on Compensation

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

The study will be the first to assess the impact of nicotine concentration on compensatory puffing (total inhaled volume), nicotine delivery, and switch patterns (percent exclusive EC, dual cig-EC, and cig only users) with an explicit focus on AA and White smokers.

NCT ID: NCT05887401 Active, not recruiting - Cancer Clinical Trials

Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

Start date: October 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this pilot randomized factorial trial is to test the feasibility, acceptability, and effects of a theory-based mobile physical activity and nutrition intervention designed specifically for young adult cancer survivors to increase physical activity and diet quality.

NCT ID: NCT05887323 Active, not recruiting - Heart Failure Clinical Trials

LBBAP Data Collection Registry

Start date: April 25, 2023
Phase:
Study type: Observational

The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.